|
Active substance |
lacosamide |
|
Holder |
UCB Pharma SA |
|
Status |
Closed |
|
Indication |
Adjuvant therapy in the treatment of partial seizures with or without secondary generalization in adults, adolescents and children from 4 years old with epilepsy |
|
Public documents |
|
|
Last update |
10/08/2022 |
Vimpat®
Last updated on 10/09/2024